Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary ...

As of March 31, 2025, the Company’s cash, cash equivalents and investments was $314.2 million. The Company expects that its cash, cash equivalents and investments, as of March 31, 2025, will fund its ...

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination ...

MAPLE-HCM met its primary endpoint, demonstrating a statistically significant improvement in peak oxygen uptake (pVO 2) from ...

The Crypto Council for Innovation is making a case with the U.S. Securities and Exchange Commission that staking is not only a virtue for digital asset markets, but it should be hands-off for the ...

Genmab Announces Financial Results for the First Quarter of 2024May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025HighlightsEPKINLY® (epcoritamab) approved by ...

Hicklin, Ph.D., President and Chief Executive Officer of Werewolf ... "Risk Factors" section of the Company's most recent Form 10-K filed with the Securities and Exchange Commission (SEC), and in ...

Detailed price information for Werewolf Therapeutics Inc (HOWL-Q) from The Globe and Mail including charting and trades.

AMH (NYSE: AMH) (the "Company"), a leading large-scale integrated owner, operator and developer of single-family rental homes, today announced that the Board of Trustees declared a dividend of $0.30 ...

characters or trends "for which the promoter seeks to attract an enthusiastic online community to purchase the meme coin and engage in its trading," according to the Securities and Exchange Commission ...

Neurocrine Biosciences, Inc. today announced its financial results for the first quarter ended March 31, 2025, and reaffirms its 2025 financial ...